anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIM: Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC) is rapidly spreading. The robotic surgical techniques to approach lateral invasion, such as that of the pelvic plexus, have not yet been established. In this technical note, we present a video illustrating a surgical technique for lateral invasion using our novel technique and discuss its pitfalls.
METHOD: We present the case of a 65-year-old man with LARC. Robotic surgery was performed after TNT using the da Vinci Xi Surgical System (Intuitive Surgical Inc., Sunnyvale, CA, USA). The surgical procedure was as follows: (1) D3 lymph node dissection around the inferior mesenteric artery using a medial-to-lateral approach; (2) rectal mobilization; (3) dissection of the ureterohypogastric fascia and ureter; and (4) combined resection of the hypogastric nerve and pelvic plexus. The key surgical point for sidewall invasion is the resection extent. Dividing the resection extent into three areas is important: zone A, which contains the pelvic plexus and is closest to the tumour; zone B, which contains the iliac vessels; and zone C, the most lateral zone, which contains the obturator nerves. This allows organ and function preservation by resecting only the smallest organ that truly requires R0 resection.
RESULTS: The operating time was 333 min, console time was 232 min, and blood loss was 0 mL. The circumferential resection margin was 10 mm, and an R0 resection was achieved.
CONCLUSION: We introduced a novel approach for robotic surgery after TNT for LARC with sidewall invasion. This technique can be performed safely and may help standardize 'beyond total mesorectal excision'.
Defined as scarce expression of hormone receptors and human epidermal growth factor receptor 2, triple-negative breast cancer (TNBC) is labeled as the most heterogeneous subtype of breast cancer with poorest prognosis. Despite rapid advancements in precise subtyping and tailored therapeutics, the ensuing cancer therapy-related cardiovascular toxicity (CTR-CVT) could exert detrimental impacts to TNBC survivors. Nowadays, this interdisciplinary issue is incrementally concerned by cardiologists, oncologists and other pertinent experts, propelling cardio-oncology as a booming field focusing on the whole-course management of cancer patients with potential cardiovascular threats. Here in this review, we initially profile the evolving molecular subtyping and therapeutic landscape of TNBC. Further, we introduce various monitoring approaches of CTR-CVT. In the main body, we elaborate on typical cardiotoxicities ensuing anti-TNBC treatments in detail, ranging from chemotherapy (especially anthracyclines), surgery, anesthetics, radiotherapy to immunotherapy, with future perspectives on promising directions in the era of artificial intelligence and traditional Chinese medicine.
Effective communication of imaging findings in term hypoxic ischemic injury to family members, non-radiologist colleagues and members of the legal profession can be extremely challenging through text-based radiology reports. Utilization of three-dimensional (D) printed models, where the actual findings of the brain can be communicated via tactile perception, is a potential solution which has not yet been tested in practice. We aimed to determine the sensitivity and specificity of different groups, comprising trained radiologists, non-radiologist physicians and non-physicians, in the detection of gross disease of the cerebral cortex from 3-D printed brain models derived from magnetic resonance imaging (MRI) scans of children. Ten MRI scans in children of varying ages with either watershed pattern hypoxic ischemic injury (cortical injury) or basal-ganglia-thalamus hypoxic ischemic injury pattern with limited perirolandic cortical abnormalities and 2 normal MRI scans were post processed and 3-D printed. In total, 71 participants reviewed the 12 models and were required to indicate only the brain models that they felt were abnormal (with a moderate to high degree of degree of confidence). The 71 participants included in the study were 38 laypeople (54%), 17 radiographic technologists (24%), 6 nurses (8%), 5 general radiologists (7%), 4 non-radiologist physicians- 3 pediatricians and 1 neurologist (6%) and 1 emergency medical services staff (1%). The sensitivity and specificity for detecting the abnormal brains of the 71 participants were calculated. Radiologists showed the highest sensitivity (72%) and specificity (70%). Non-radiologist physicians had a sensitivity of 67.5% and a specificity of 75%. Nurses had a sensitivity of 70% and a specificity of 41.7%. Laypeople (non-medical trained) had a sensitivity of 56.1% and a specificity of 55.3%. Radiologists' high sensitivity and specificity of 72% and 70%, respectively, validates the accuracy of the 3-D-printed models in reproducing abnormalities from MRI scans. The non-radiologist physicians also had a high sensitivity and specificity. Laypeople, without any prior training or guidance in looking at the models, had a sensitivity of 56.1% and a specificity of 55.3%. These results show the potential for use of the 3-D printed brains as an alternate form of communication for conveying the pathological findings of hypoxic ischemic injury of the brain to laypeople.
The invention relates to a manganese dioxide-based nano-drug carrier, and creatively combines a hunger therapy and a gas therapy to treat cancers. Specifically, folic acid targeting molecules are introduced to human serum albumin by amidation reaction, and then the nano manganese dioxide carrier is cultured in the protein by a biomineralization method. Glucose oxidase and L-arginine are loaded simultaneously through physical adsorption. The advantages are that: 1. greatly improves the targeting drug delivery efficiency and the dispersibility of the nano manganese dioxide. 2. The cancer cells are killed by starvation and gas therapy using specific chemical reactions within the cancer cells consuming endogenous glucose and releasing nitric oxide gas. 3. The synthetic carrier material is degradable, and the loaded enzyme and amino acid are endogenous substances of human bodies and have no toxic or side effect on the human bodies. 4. Has obvious anticancer effect and can kill cancer cells at very low biological enzyme concentration.
Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study.
Provided are homeopathic compositions and methods for the preparation and use of such homeopathic compositions. Therapeutic methods comprise the administration of combinations of homeopathic compositions to provide the effective treatment of cancer, such as prostate cancers. Homeopathic compositions may be prepared by extracting from a patient a tissue sample comprising a tumor cell and a reactive tissue cell that is located in proximity to the tumor cell. Such a tissue sample is suspended in a liquid carrier solution and succussed serially in a liquid carrier solution to provide the homeopathic composition having a homeopathic potency. Homeopathic methods comprise the administration of a homeopathic composition optionally in combination with a second homeopathic composition. Exemplary second homeopathic compositions include  Thuja occidentalis, Conium maculaturm,  and  Sabal serulata.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to novel derivatives of 2- (1,2,4-triazole-1-yl)-1,3,4-thiadiazole of the formula (I)   where R 1  means hydrogen atom, C 1-4 -alkyl group or phenyl group that can be substituted with from 1 to 3 substituents taken among the group including halogen atom, hydroxy-group, nitro-group, C 1-4 -alkoxy-group, (C 1-4 - alkyl)-amino-group and di-( -alkyl)-amino-group; or the group of the formula (a) C 1-4 ; Z means hydrogen atom or C 1-4 -alkoxy-group; R 0  means the group of the formula Alk-NR 4 R 5  where Alk is alkylene group with direct or branched C 1-6 -chain; one of R 2  and R 3  means amino-group and another one means amino-group or 5-6-membered saturated heterocyclic group including one or two nitrogen and/or oxygen atoms that is bound through its nitrogen atom being the indicated heterocyclic group can be substituted with C 1-4 -alkyl group, phenyl group or halogenphenyl group or the latter of R 2  and R 3  means the group of the formula -SR. Compounds show effect on heart and central nervous system. Also, invention describes method of synthesis of novel compounds, intermediate substances and pharmaceutical compositions based on these novel compounds. EFFECT: new compounds indicated above, improved method of synthesis, valuable medicinal properties. 18 cl, 4 tbl
The invention belongs to the technical field of traditional Chinese medicine cosmetology, and relates to traditional Chinese medicine mask powder capable of expelling toxins and removing acnes and a preparation method thereof. Pure traditional Chinese medicine components, no desquamation, no red swelling, no addition of any harmful chemical substances and hormone components, and no side effect. No scar left and no recurrence. Has effects of clearing heat-fire, promoting blood circulation, relieving inflammation, removing toxic substance, removing acne, whitening and caring skin. Is suitable for use in: acne (whelk), furunculosis, skin allergy, cosmetic allergy and the like. Has the characteristics of no scar left after sore treatment and no scar left after acne treatment.
BACKGROUND: Microvascular decompression (MVD) is an effective method for directly treating hemifacial spasms (HFS). The timing for the consideration of failed MVD and reoperation has been paradoxical.
OBJECTIVE: This study aimed to investigate the delayed complete remission of HFS in terms of prevalence rate, duration between surgery and delayed complete remission, and predictive factors.
METHODS: A hundred patients with HFS who underwent MVD from 2012-2021 were enrolled in the study. All HFS occurred as a result of compression of the facial nerve by adjacent blood vessels. Clinical information, intraoperative findings, and surgical outcomes were incorporated for data analysis.
RESULTS: In the first week after MVD, 67 of 100 patients achieved complete remission of HFS, while the remaining 33 had incomplete remission. In long-term follow-up, 26 individuals gradually developed delayed complete remission with a median duration of 9.1 months. Finally, 86 of 100 patients achieved complete long-term remission. Recurrent HFS and incomplete remission were found in 7 and 7 patients, respectively. Factors associated with postoperative complete remission in the first week were a severe degree of facial nerve compression (p = 0.047, OR 2.75, 95% CI 1.01-7.40), with long-term complete remission was left-sided HFS (p = 0.012, OR 5.73, 95% CI 1.47-22.36), and with the appearance of delayed complete remission was the prolonged duration of HFS at least 3 years before MVD (p = 0.046, OR 3.75, 95% CI 1.03-13.76). Transient facial paresis was found in 11% of the patients. Of them, facial nerve function recovered completely in all cases.
CONCLUSIONS: A delayed complete remission of HFS could be expected in long-term follow-up after MVD and is probably related to a longer duration of HFS before surgery. Unnecessary reoperation should be avoided in the early years following the first surgery.
The method comprises connecting a molded part (10) with a carrier (14), which is produced from a blank, over a first connector (20, 22, 24) such as a web or membrane during sintering. The carrier is produced as a section of the blank section-wisely and circumferentially surrounding the molded part by material-removal process from the blank. After the production of the carrier, a second connector (16, 18) is connected with a residual blank (12) section-wisely spatially surrounding the carrier. The carrier circumferentially surrounds the molded part and is milled out from the blank. The method comprises connecting a molded part (10) with a carrier (14), which is produced from a blank, over a first connector (20, 22, 24) such as a web or membrane during sintering. The carrier is produced as a section of the blank section-wisely and circumferentially surrounding the molded part by material-removal process from the blank. After the production of the carrier, a second connector (16, 18) is connected with a residual blank (12) section-wisely spatially surrounding the carrier. The carrier circumferentially surrounds the molded part and is milled out from the blank, so that the carrier is connected with the molded part over a first membrane and/or over two first webs and is connected with the remaining residual blank over a second membrane and/or over two second webs. The molded part and the carrier restoringly pass to a section of outer surface of the residual blank and/or the frame, on which the residual blank is positioned at a base during sintering. The carrier with the molded part is separated from the residual blank before completely sintering. The carrier remains unmachined in its height. Each molded part is surrounded by the common carrier, and is surrounded as carrier, whose progression follows circumferential contour of the molded part, by the frames. A disk is used as the blank. A seven-membered dental bridge is produced as the molded part from the blank. An independent claim is included for a residual blank as a part of a blank consisting of a ceramic material.
Diabetes mellitus and obesity are rapidly growing worldwide. Aside from metabolic disturbances, these two disorders also affect bone with a higher prevalence of bone fractures. In the last decade, a growing body of evidence suggested that several gut hormones, including ghrelin, gastrin, glucose-dependent insulinotropic polypeptide (GIP), glucagon, and glucagon-like peptide-1 and 2 (GLP-1 and GLP-2, respectively) may affect bone physiology. Several gut hormone analogues have been developed for the treatment of type 2 diabetes and obesity, and could represent a new alternative in the therapeutic arsenal against bone fragility. In the present review, a summary of the physiological roles of these gut hormones and their analogues is presented at the cellular level but also in several preclinical models of bone fragility disorders including type 2 diabetes mellitus, especially on bone mineral density, microarchitecture and bone material properties. The present review also summarizes the impact of GLP-1 receptor agonists approved for the treatment of type 2 diabetes mellitus and the more recent dual or triple analogue on bone physiology and strength.
Participants in the Balance Trainer group were included to exercise program that consisted of 16 individual PT-supervised sessions (two 60-minute sessions/week), which were prepared to improve balance. Each session started with 10 minutes of non-resistance cycling work for warm-up.
Fludeoxyglucose F 18 is a glucose analog that concentrates in cells that rely upon glucose as an energy source, or in cells whose dependence on glucose increases under pathophysiological conditions.

Fludeoxyglucose F 18 is transported through the cell membrane by facilitative glucose transporter proteins and is phosphorylated within the cell to [18F] FDG-6-phosphate by the enzyme hexokinase. Once phosphorylated it cannot exit until it is dephosphorylated by glucose-6-phosphatase. Therefore, within a given tissue or pathophysiological process, the retention and clearance of Fludeoxyglucose F 18 reflect a balance involving glucose transporter, hexokinase and glucose-6-phosphatase activities. Fludeoxyglucose F 18 is used to assess glucose metabolism.

In comparison to background activity of the specific organ or tissue type, regions of decreased or absent uptake of Fludeoxyglucose F 18 reflect the decrease or absence of glucose metabolism. Regions of increased uptake of Fludeoxyglucose F 18 reflect greater than normal rates of glucose metabolism.
Environmental antineoplastics such as sorafenib may pose a risk to humans through water recycling, and the increased risk of cardiotoxicity is a clinical issue in sorafenib users. Thus, developing strategies to prevent sorafenib cardiotoxicity is an urgent work. Empagliflozin, as a sodium-glucose co-transporter-2 (SGLT2) inhibitor for type 2 diabetes control, has been approved for heart failure therapy. Still, its cardioprotective effect in the experimental model of sorafenib cardiotoxicity has not yet been reported. Real-time quantitative RT-PCR (qRT-PCR), immunoblot, and immunohistochemical analyses were applied to study the effect of sorafenib exposure on cardiac SGLT2 expression. The impact of empagliflozin on cell viability was investigated in the sorafenib-treated cardiomyocytes using Alamar blue assay. Immunoblot analysis was employed to delineate the effect of sorafenib and empagliflozin on ferroptosis/proinflammatory signaling in cardiomyocytes. Ferroptosis/DNA damage/fibrosis/inflammation of myocardial tissues was studied in mice with a 28-day sorafenib ± empagliflozin treatment using histological analyses. Sorafenib exposure significantly promoted SGLT2 upregulation in cardiomyocytes and mouse hearts. Empagliflozin treatment significantly attenuated the sorafenib-induced cytotoxicity/DNA damage/fibrosis in cardiomyocytes and mouse hearts. Moreover, GPX4/xCT-dependent ferroptosis as an inducer for releasing high mobility group box 1 (HMGB1) was also blocked by empagliflozin administration in the sorafenib-treated cardiomyocytes and myocardial tissues. Furthermore, empagliflozin treatment significantly inhibited the sorafenib-promoted NFκB/HMGB1 axis in cardiomyocytes and myocardial tissues, and sorafenib-stimulated proinflammatory signaling (TNF-α/IL-1β/IL-6) was repressed by empagliflozin administration. Finally, empagliflozin treatment significantly attenuated the sorafenib-promoted macrophage recruitments in mouse hearts. In conclusion, empagliflozin may act as a cardioprotective agent for humans under sorafenib exposure by modulating ferroptosis/DNA damage/fibrosis/inflammation. However, further clinical evidence is required to support this preclinical finding.
FIELD: biology, biochemistry, medicine, proteins. SUBSTANCE: invention relates to the novel isolated and purified protein produced by brain endothelial cells. Molecular mass of this protein is about 67 kDa by data of electrophoresis on polyacrylamide gel with sodium dodecyl sulfate. This protein is able to stimulate proliferation of cerebral arteriole smooth muscle cells. Invention describes also the composition containing the novel protein by p. 1 of the invention claim. Invention provides preparing the novel agent for prophylaxis or treatment of many diseases of brain vessels. EFFECT: new protein indicated above, valuable medicinal properties of protein. 2 cl, 7 dwg, 6 ex
NEW MATERIAL:A glycerol derivative of formula I (R1 is 8-18C straight- or branched-chain alkyl; R2 is H, 1-4C alkyl, acyl; n is 3-5). EXAMPLE:N-(2-Hydroxy-3-dodecyloxypropyl)-epsilon-caprolactam. USE:A compound manifesting action to promote the absorption of medicinal component into living bodies. It has excellent permeability through biomembranes, but shows reduced irritation to skins. PREPARATION:For example, a glycidyl ether of formula II is allowed to react with a lactam of formula III to give a compound of formula Ia. Then, the product is allowed to react with an alkylating or acylating agent to give a compound of formula Ia.
PURPOSE:To obtain an anti-inflammatory composition for oral cavity excellent in action on inflammatory diseases and especially useful for preventing and treating periodontal diseases such as periodontitis by including a specific triterpenoid as an active ingredient. CONSTITUTION:A anti-inflammatory composition for oral cavity contains triterpenoid obtained by extracting from a sponge gourd, etc., as an active ingredient. The triterpenoid includes especially bryonolic acid or its salt or its dicarboxylic acid ester. As the triterpenoid, an extract of cucuribitaceous plant (especially preferably the sponge gourd) or extract of callus induced by tissue culture of cucuribitaceous plant is used. Remarkable effect is exhibited for preventing and treating periodontal disease by locally administering these effective ingredients. This composition can preferably be used as a composition for applying to oral cavity, e.g. tooth paste, tooth powder, liquid tooth, mouth- washing agent, ointment, gel, pasta, troche or chewing gum.
Hepatic stellate cells (HSCs) play a role in hepatic fibrosis and sphingosine kinase (SphK) is involved in biological processes. As studies on the regulatory mechanisms and functions of SphK in HSCs during liver fibrosis are currently limited, this study aimed to elucidate the regulatory mechanism and connected pathways of SphK upon HSC activation. The expression of SphK1 was higher in HSCs than in hepatocytes, and upregulated in activated primary HSCs. SphK1 was also increased in liver homogenates of carbon tetrachloride-treated or bile duct ligated mice and in transforming growth factor-β (TGF-β)-treated LX-2 cells. TGF-β-mediated SphK1 induction was due to Smad3 signaling in LX-2 cells. SphK1 modulation altered the expression of liver fibrogenesis-related genes. This SphK1-mediated profibrogenic effect was dependent on SphK1/sphingosine-1-phosphate/sphingosine-1-phosphate receptor signaling through ERK. Epigallocatechin gallate blocked TGF-β-induced SphK1 expression and hepatic fibrogenesis by attenuating Smad and MAPK activation. SphK1 induced by TGF-β facilitates HSC activation and liver fibrogenesis, which is reversed by epigallocatechin gallate. Accordingly, SphK1 and related signal transduction may be utilized to treat liver fibrosis.
Participants with Down syndrome receive dose X of ACI-24.060 at predefined time points over 74 weeks. Dose X will be a dose already tested in Study Part 1.
There are numerous reports in the literature on drainage options after TKA, but there is no consensus. Many studies have shown no apparent advantage of drainage but routine intraarticular indwelling drainage after TKA has been extensively used to avoid complications associated with hematoma formation. It is of interest to determine if it is possible to reduce blood loss while still using drainage. So we came to think about a new and more convenient method-subcutaneous indwelling. Theoretically subcutaneous indwelling method which still has the advantages over the intraarticular indwelling method but is more convenient than drain-clamping method may be a better option. So we hypothesized that subcutaneous indwelling method of vacuum drainage has advantages over the intraarticular indwelling method.
This study based on Shanghai pregnancy population is a prospective birth cohort. The investigators obtain the data of participants' folic acid and vitamin D supplement intake through the questionnaire at 12-14 gestational weeks. And the investigators collect participants' blood samples during gestation to directly detect the biological exposure levels of folate and vitamin D. In the follow-up, skin barrier function is evaluated at time of infant 24-48 hours, 42 days and 6 months. During 6 months from birth, the incidence of AD is investigated on offsprings. This cohort study is aimed to (1) clarify the association between prenatal key nutrients with offspring AD; (2) assess the role of maternal key nutrients in the skin barrier of offsprings. It will be a good evidence for the AD prevention and a meaningful protocol to reduce the incidence of AD by its unique design.Univariate and multivariate association analyses will be performed to identify risk factors to AD by using multivariate logistic regression model.